Treatment of unresectable or metastatic gallbladder cancer with single-agent gemcitabine or in combination with cisplatin

• DOI: 10.1200/jco.2005.23.16_suppl.4211
• Publication Date: 2017-02-23T13:55:09Z
• Authors: J. Gallardo; B. Rubio; O. Barajas; L. Villanueva; M. Fodor
• Keywords: Gallbladder Cancer; Clinical endpoint

4211 Background: Gallbladder carcinomas (GC) are often diagnosed at an advanced/metastatic stage amenable only to palliative surgery. Published data on CT for GC quite scarce and frequently, erroneously mixed with others biliary tract cancers, their median survival is around 8 12 weeks. Results of chemotherapy advanced extremely poor traditional treatment based 5-FU. Methods: Since 1997 we have been studying the effect gemcitabine. We retrospectively reviewed two different protocol treatments, made possible. In both trials pts had similar characteristics, they all measurable locally or metastatic histological cytological proof, no prior radiotherapy. The main endpoint was RR secondary endpoints were toxicity overall survival. outcomes. first trial 26 treated GEM 1000 mg/m2 i.v. 30 minutes weekly 3 weeks out every 4 until disease progression and/or toxicity. second cohort, 44 received Gem 1200 Cis 35 d1and 8, 21d a total 6 courses. evaluated by abdominal scan. Pts outpatient basis. Results: Twenty-five 42 were, response. There 0/4 CRs 9/16 PRs gem vs + cispl. All Four 1 died due progression, one pt. renal in arm +cispl. pt occurred hepatotoxicity grade alone. hematology toxicities included thrombocytopenia (0% 2%), neutropenia (3.8% 23%) anemia 14%) group Median time 8.7 mos. 7 entire population, 14.1 9 responders, 6.1 vs. 5 non-responders. Conclusions: active against advanced, unresectable recurrent good tolerability. low profile should be considered when choice patient GC. combined cisplatin, resulting increased frequency severity side effects not improved rates responses comparison alone No significant financial relationships disclose.